MYGN
Myriad Genetics, Inc. NASDAQ Listed Oct 6, 1995$4.09
Mkt Cap $382.4M
52w Low $3.75
7.0% of range
52w High $8.59
50d MA $4.79
200d MA $6.04
P/E (TTM)
-1.2x
EV/EBITDA
-1.6x
P/B
1.2x
Debt/Equity
0.6x
ROE
-99.4%
P/FCF
318.8x
RSI (14)
—
ATR (14)
—
Beta
1.64
50d MA
$4.79
200d MA
$6.04
Avg Volume
1.7M
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
320 Wakara Way · Salt Lake City, UT 84108 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | -0.06 | -0.36 | -500.0% | 5.03 | -17.9% | -18.3% | -18.7% | — | — | — | — |
| Feb 23, 2026 | AMC | -0.02 | 0.04 | +300.0% | 4.38 | +27.2% | +1.1% | +9.1% | +11.0% | +5.3% | +14.4% | — |
| Nov 3, 2025 | AMC | -0.01 | -0.13 | -1200.0% | 8.18 | -9.3% | -21.0% | -19.6% | -22.6% | -23.0% | -20.8% | — |
| Aug 5, 2025 | AMC | -0.01 | 0.05 | +600.0% | 3.87 | +34.1% | +46.5% | +57.6% | +63.3% | +59.9% | +55.8% | — |
| May 6, 2025 | AMC | -0.05 | -0.03 | +40.0% | 7.27 | -21.6% | -41.3% | -44.6% | -46.5% | -41.5% | -43.5% | — |
| Feb 24, 2025 | AMC | 0.03 | 0.03 | +0.0% | 13.78 | -25.1% | -14.8% | -16.1% | -19.7% | -22.1% | -24.6% | — |
| Nov 7, 2024 | AMC | 0.02 | 0.06 | +215.8% | 17.67 | +3.6% | -1.5% | -2.0% | -8.5% | -10.7% | -11.3% | — |
| Aug 6, 2024 | AMC | 0.01 | 0.05 | +509.1% | 25.96 | +10.0% | +2.6% | +6.6% | +7.7% | +7.7% | +8.6% | — |
| May 7, 2024 | AMC | -0.11 | -0.01 | +90.9% | 19.78 | +18.6% | +21.1% | +27.7% | +28.8% | +26.0% | +28.2% | — |
| Feb 27, 2024 | AMC | 0.01 | 0.04 | +214.5% | 23.50 | -1.1% | -8.0% | -10.9% | -5.6% | -6.5% | -5.4% | — |
| Nov 6, 2023 | AMC | -0.08 | -0.03 | +62.5% | 16.34 | +4.8% | +8.7% | +9.5% | -0.3% | +0.7% | +0.9% | — |
| Aug 3, 2023 | AMC | -0.10 | -0.08 | +20.0% | 20.76 | -6.1% | -7.0% | -15.8% | -17.8% | -18.4% | -19.6% | — |
| May 3, 2023 | AMC | -0.19 | -0.21 | -10.5% | 21.89 | -12.5% | -3.7% | -11.9% | -16.3% | -17.8% | -18.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $4.38 | $5.57 | +27.2% | +1.1% | +9.1% | +11.0% | +5.3% | +14.4% |
| Feb 24 | UBS | Maintains | Neutral → Neutral | — | $4.38 | $5.57 | +27.2% | +1.1% | +9.1% | +11.0% | +5.3% | +14.4% |
| Nov 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.48 | $6.45 | -0.5% | +3.1% | +0.9% | -2.0% | +3.5% | +2.8% |
| Nov 5 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $6.46 | $6.42 | -0.6% | +1.9% | -2.0% | -2.5% | +0.3% | +3.4% |
| Nov 4 | TD Cowen | Maintains | Hold → Hold | — | $8.18 | $7.42 | -9.3% | -21.0% | -19.6% | -22.6% | -23.0% | -20.8% |
| Nov 4 | UBS | Maintains | Neutral → Neutral | — | $8.18 | $7.42 | -9.3% | -21.0% | -19.6% | -22.6% | -23.0% | -20.8% |
| May 21 | Scotiabank | Downgrade | Sector Outperform → Sector Perform | — | $4.45 | $4.25 | -4.5% | -8.5% | -11.7% | -12.1% | -6.7% | -2.7% |
| May 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.84 | $3.88 | +1.0% | +7.0% | +7.6% | +15.4% | +15.9% | +6.0% |
| May 8 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $4.27 | $4.29 | +0.5% | -5.6% | -8.9% | -0.5% | -3.7% | -10.1% |
| May 7 | UBS | Maintains | Neutral → Neutral | — | $7.27 | $5.70 | -21.6% | -41.3% | -44.6% | -46.5% | -41.5% | -43.5% |
| May 7 | Goldman Sachs | Maintains | Buy → Buy | — | $7.27 | $5.70 | -21.6% | -41.3% | -44.6% | -46.5% | -41.5% | -43.5% |
| May 7 | Raymond James | Maintains | Outperform → Outperform | — | $7.27 | $5.70 | -21.6% | -41.3% | -44.6% | -46.5% | -41.5% | -43.5% |
| Apr 17 | Goldman Sachs | Maintains | Buy → Buy | — | $7.91 | $7.86 | -0.6% | -3.4% | -6.4% | -6.1% | -7.8% | -6.8% |
| Apr 9 | Guggenheim | Downgrade | Buy → Neutral | — | $7.73 | $7.37 | -4.7% | +9.3% | +2.8% | +3.5% | +4.5% | +3.6% |
| Apr 1 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $8.87 | $8.91 | +0.5% | -0.3% | -0.8% | -5.2% | -8.3% | -9.0% |
| Mar 12 | Piper Sandler | Upgrade | Neutral → Overweight | — | $10.25 | $10.90 | +6.3% | +1.6% | -5.4% | -1.8% | -1.3% | -3.4% |
| Mar 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $10.39 | $10.25 | -1.3% | +0.3% | -0.5% | +1.3% | -2.0% | -7.6% |
| Mar 3 | BofA Securities | Maintains | Underperform → Underperform | — | $10.73 | $10.85 | +1.1% | -3.2% | -2.9% | -3.6% | -2.0% | -5.1% |
| Feb 25 | Raymond James | Maintains | Outperform → Outperform | — | $13.78 | $10.32 | -25.1% | -14.8% | -16.1% | -19.7% | -22.1% | -24.6% |
| Feb 25 | UBS | Maintains | Neutral → Neutral | — | $13.78 | $10.32 | -25.1% | -14.8% | -16.1% | -19.7% | -22.1% | -24.6% |
| Jan 30 | Piper Sandler | Maintains | Neutral → Neutral | — | $12.54 | $12.60 | +0.5% | +3.0% | +1.0% | +1.8% | -1.0% | +3.1% |
| Jan 28 | Goldman Sachs | Maintains | Buy → Buy | — | $12.96 | $12.91 | -0.4% | -3.5% | -3.2% | -0.4% | -2.2% | -1.5% |
| Jan 16 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $13.15 | $13.15 | +0.0% | -4.8% | -5.8% | -4.4% | -6.6% | -3.0% |
| Dec 13 | BofA Securities | Maintains | Underperform → Underperform | — | $14.50 | $14.34 | -1.1% | -0.5% | -2.6% | -4.7% | -8.6% | -9.2% |
| Dec 9 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $15.13 | $14.85 | -1.9% | -1.7% | +1.4% | -4.1% | -4.2% | -4.6% |
| Nov 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $15.25 | $15.05 | -1.3% | -0.2% | -1.6% | +0.3% | -0.9% | +1.6% |
| Nov 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $17.41 | $17.33 | -0.5% | -0.6% | -7.1% | -9.4% | -9.9% | -12.4% |
| Aug 13 | Piper Sandler | Maintains | Neutral → Neutral | — | $27.95 | $28.29 | +1.2% | +0.8% | -1.2% | -0.4% | +0.8% | +1.1% |
| Aug 13 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $27.95 | $28.29 | +1.2% | +0.8% | -1.2% | -0.4% | +0.8% | +1.1% |
| Aug 7 | JP Morgan | Maintains | Underweight → Underweight | — | $25.96 | $28.55 | +10.0% | +2.6% | +6.6% | +7.7% | +7.7% | +8.6% |
| Aug 7 | TD Cowen | Maintains | Hold → Hold | — | $25.96 | $28.55 | +10.0% | +2.6% | +6.6% | +7.7% | +7.7% | +8.6% |
| May 13 | Piper Sandler | Maintains | Neutral → Neutral | — | $25.47 | $25.48 | +0.0% | -2.1% | -0.4% | -3.2% | -3.4% | -0.7% |
| May 8 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $19.78 | $23.45 | +18.6% | +21.1% | +27.7% | +28.8% | +26.0% | +28.2% |
| Jan 30 | Goldman Sachs | Maintains | Buy → Buy | — | $22.72 | $22.72 | +0.0% | -0.9% | -5.9% | -4.9% | -6.4% | -3.8% |
| Jan 29 | Goldman Sachs | Maintains | Buy → Buy | — | $22.22 | $22.37 | +0.7% | +2.3% | +1.3% | -3.7% | -2.7% | -4.3% |
| Nov 7 | JP Morgan | Maintains | Underweight → Underweight | — | $16.34 | $17.12 | +4.8% | +8.7% | +9.5% | -0.3% | +0.7% | +0.9% |
| Aug 7 | JP Morgan | Maintains | Underweight → Underweight | — | $19.31 | $19.18 | -0.7% | -9.5% | -11.7% | -12.3% | -13.6% | -7.4% |
| Jul 24 | Goldman Sachs | Maintains | Buy → Buy | — | $23.08 | $23.00 | -0.3% | -4.6% | -4.0% | -4.3% | -5.8% | -2.8% |
| Jul 21 | Goldman Sachs | Maintains | Buy → Buy | — | $22.18 | $22.59 | +1.8% | +4.1% | -0.7% | -0.1% | -0.4% | -1.9% |
| May 24 | Goldman Sachs | Maintains | Buy → Buy | — | $22.68 | $22.64 | -0.2% | +1.1% | -2.5% | -1.7% | -1.9% | -2.7% |
| May 23 | Goldman Sachs | Upgrade | Sell → Buy | — | $20.07 | $21.97 | +9.5% | +13.0% | +14.3% | +10.2% | +11.1% | +10.9% |
| May 4 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $21.89 | $19.15 | -12.5% | -3.7% | -11.9% | -16.3% | -17.8% | -18.8% |
| May 4 | Goldman Sachs | Maintains | Sell → Sell | — | $21.89 | $19.15 | -12.5% | -3.7% | -11.9% | -16.3% | -17.8% | -18.8% |
| Mar 6 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $23.26 | $23.41 | +0.6% | -5.0% | -6.7% | -6.1% | -7.2% | -8.7% |
| Mar 3 | Raymond James | Maintains | Outperform → Outperform | — | $22.90 | $23.30 | +1.7% | +1.6% | -3.5% | -5.2% | -4.6% | -5.7% |
| Jan 18 | Raymond James | Upgrade | Market Perform → Outperform | — | $18.56 | $19.90 | +7.2% | +5.9% | +5.1% | +9.6% | +15.4% | +13.0% |
| Nov 2 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $17.50 | $17.31 | -1.1% | -6.9% | -9.8% | -5.5% | -6.9% | +2.9% |
| Oct 6 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $20.82 | $20.62 | -1.0% | -2.0% | -5.8% | -8.9% | -10.6% | -9.1% |
| Aug 5 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $27.40 | $27.08 | -1.2% | +0.2% | -1.0% | -4.4% | +0.3% | -2.6% |
| May 5 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $21.85 | $21.00 | -3.9% | -1.1% | -1.6% | -9.9% | -9.1% | -9.2% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Leadership transitions with equity incentives can signal confidence in succession planning, but investors should monitor whether new executives meet performance targets to ensure shareholder value isn't diluted through excessive equity grants.
Mar 16
8-K
Myriad Genetics Inc -- 8-K Filing
Myriad Genetics disclosed financial information in an 8-K filing with limited liability protection, indicating the company provided guidance or results that won't be incorporated into future securities filings unless explicitly referenced.
Feb 23
Data updated apr 26, 2026 2:02pm
· Source: massive.com